



165 – 10551 Shellbridge Way
Richmond, BC, V6X 2W8

BIOMARK SCIENTIFIC ADVISOR DR. DONALD MILLER TO PRESENT AT THE DELAWARE VALLEY DRUG METABOLISM DISCUSSION GROUP

Vancouver, British Columbia – (September 23rd, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that on September 29, its strategic scientific advisor Dr. Donald Miller is to present on BioMark’s SSAT amantadine assay for the early detection of cancer at the prestigious Delaware Valley Drug Metabolism Discussion Group (DVDMDG).

Rashid Ahmed, President and CEO of BioMark, says, “We are pleased to have Dr. Donald Miller present his important work on the SSAT amantadine assay for the early detection of cancer in such an excellent forum with the distinguished Delaware Valley Drug Metabolism Discussion Group. Don’s work on biomarkers and the blood-brain barrier, as relates to cancer, is a crucial part of BioMark’s mission to use biomarkers to diagnose and monitor cancers early. His talk will increase BioMark’s visibility to companies in the Biopharma and diagnostics space and will further support the scientific foundation of BioMark’s technology platform.”

The DVDMDG takes place online on September 22 and September 29, Eastern time. Dr. Miller is presenting on September 29 at 2pm. For more information, please refer to the DVDMDG website at: <https://www.dvdmdg.org/>

About Dr. Donald Miller

Dr. Donald Miller is a Professor in the Department of Pharmacology and Therapeutics at the University of Manitoba. He received his B.Sc. in Chemistry from Bethel College (1985), Newton, Kansas, and his Ph.D. in Pharmacology and Toxicology from the University of Kansas (1991). He was a Marion Merrell Dow Postdoctoral Research Fellow in Dr. Ronald Borchardt’s laboratory at the University of Kansas where he studied biological approaches for enhancing drug delivery and drug absorption (1991-1993). Dr. Miller is an internationally recognized expert in drug transporters and blood-brain barrier function, having served on both NIH and CIHR grant and fellowship review panels, as well as reviewer and site visit examiner for Austrian and European Union based program grant initiatives. Dr. Miller’s research program includes examination of blood-brain barrier changes during brain tumor development and identification of methods for increasing the delivery of chemotherapeutic agents to brain tumor; identification and characterization of drug efflux transport proteins in the blood-brain barrier and the molecular mechanisms influencing activity and expression; and the design and development of nanoparticle drug delivery platforms for CNS applications.

About the Delaware Valley Drug Metabolism Discussion Group (DVDMDG)

The DVDMDG provides scientists with a forum to discuss current topics in the drug metabolism sciences and includes scientists from most of the major pharmaceutical companies in the Philadelphia area as well as many local universities and laboratories. The continued growth of the organization since its founding in 1975 attests to the relevance and utility of the group.

About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website <https://thecse.com/>.

For further information on BioMark, please Contact:

Rashid Ahmed Bux

President & CEO

BioMark Diagnostics Inc.

Tel. 604-370-0779

Email: info@biomarkdiagnostics.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved or disapproved the content of this press release.